

2. (Amended) The method according to claim 1 wherein the immunomodulatory therapy is for the treatment of an autoimmune disease.

Q1 Cont
3. (Amended) The method according to claim 2 wherein the autoimmune disease is insulin-dependent diabetes mellitis, thyroiditis, atrophic gastritis (type A), pernicious anaemia, Addison's disease, pemphigus vulgaris, pemphigoid, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, discoid lupus erythematosus, haemolytic anaemia, sympathetic ophthalmia, uveitis, idiopathic thrombocytopenia, idiopathic leucopenia, primary biliary cirrhosis, autoimmune chronic active hepatitis, ulcerative colitis, Sjogren's syndrome, dermatomyositis, scleroderma or mixed connective tissue disease.

4. (Amended) The method according to claim 3 wherein the autoimmune disease is insulin-dependent diabetes mellitis.

7. (Amended) The method according to any one of claims 1 to 4 wherein the cell wall component comprises mycolyl-arabinogalactan-peptidoglycan (MAPG) or a component thereof with or without other associated cell wall components and submolecular components.

Q2
8. (Amended) The method according to claim 7 wherein MAPG is administered in combination with one or more mycolic acids, peptidoglycan or arabinogalactan.

9. (Amended) The method according to claim 7 wherein MAPG or its components are from *Mycobacterium bovis*.

10. (Amended) The method according to claim 1 wherein the mammal is a human.
